Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial

The Lancet
Apr 13, 2019  Volume 393Number 10180  p1477-1568, e37
https://www.thelancet.com/journals/lancet/issue/current

Articles
Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial
Ivermectin is widely used in mass drug administrations for controlling neglected parasitic diseases, and can be lethal to malaria vectors that bite treated humans. Therefore, it could be a new tool to reduce plasmodium transmission. We tested the hypothesis that frequently repeated mass administrations of ivermectin to village residents would reduce clinical malaria episodes in children and would be well tolerated with minimal harms.
Brian D Foy,Haoues Alout, Jonathan A Seaman, Sangeeta Rao, Tereza Magalhaes, Martina Wade, Sunil Parikh, Dieudonné D Soma, André B Sagna, Florence Fournet, Hannah C Slater,
Roland Bougma, François Drabo, Abdoulaye Diabaté, A Gafar V Coulidiaty, Nöel Rouamba,
Roch K Dabiré,
Open Access